Related Experiment Videos
Neoplastic meningitis-related encephalopathy.
Marc C Chamberlain1, Denice Tsao-Wei, Susan Groshen
1Department of Neurology, University of Southern California, Norris Comprehensive Cancer and Hospital, 1441 Eastlake Avenue, Los Angeles, CA 90033-0804, USA. chamberl@usc.edu
Journal of Neuro-Oncology
|June 1, 2005
Summary
Patients with neoplastic meningitis (NM) and encephalopathy have significantly shorter survival times. This suggests that supportive care may be the best option for patients experiencing NM-related encephalopathy.
Area of Science:
- Neuro-oncology
- Clinical Neurology
- Cancer Research
Background:
- Neoplastic meningitis (NM) is a serious complication of cancer.
- Encephalopathy in NM patients is a significant clinical challenge.
- Understanding survival factors in NM is crucial for patient care.
Purpose of the Study:
- To compare survival rates in patients with neoplastic meningitis (NM) with and without encephalopathy.
- To identify clinical factors influencing survival in NM.
- To inform treatment strategies for NM patients.
Main Methods:
- Retrospective comparison of two well-matched cohorts of NM patients (20 with encephalopathy, 20 without).
- Cohorts matched for age, primary tumor, performance status, and CNS disease characteristics.
- Analysis included patient demographics, primary tumor types, NM presentation, and treatment modalities (radiotherapy, intraventricular/systemic chemotherapy).
Main Results:
- Median survival was significantly shorter in the encephalopathy cohort (2.5 months) compared to the non-encephalopathy cohort (6 months) (p < 0.001).
- No treatment-related deaths occurred.
- All patients experienced disease progression and died from NM or systemic cancer.
Conclusions:
- NM-related encephalopathy is a strong predictor of poor survival in patients with neoplastic meningitis.
- Patients presenting with NM-related encephalopathy may benefit most from palliative and supportive care.
- This finding highlights the importance of considering encephalopathy as a key prognostic factor in NM management.